Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Dutch Elderly Care Challenges: Navigating Fragmentation in Support Systems
A recently published visualization from Zorginstituut Nederland illustrates the intricate pathways through which an elderly individual with progressive dementia, such as Mrs. Mahabier, encounters multiple statutory frameworks, care providers, and administrative entities as her needs evolve. It de...
FDA Endorses Truqap Prostate Cancer Therapy for PTEN-Deficient Cases
Truqap Prostate Cancer Therapy gains key backing from FDA advisors for PTEN-deficient metastatic hormone-sensitive prostate cancer, following strong data from the pivotal trial that demonstrated meaningful delays in disease progression.
ODAC Backs Targeted Therapy
The ...
EUCOPE Pharmaceutical Regulation: Advocating for Innovative SMEs in a Changing Landscape
EUCOPE pharmaceutical regulation shapes how innovative small and medium-sized enterprises navigate Europe's complex approval pathways. Alexander Natz, Secretary General of EUCOPE, explains how the organi...